Strontium Treatment for Pain in Prostate Cancer
Author Information
Author(s): S.D. Fosså, E. Paus, M. Lochoff, S. Melbye Backe, M. Aas
Primary Institution: The Norwegian Radium Hospital
Hypothesis
Does 89Strontium provide effective palliation for patients with hormone-resistant prostate cancer and painful bone metastases?
Conclusion
89Strontium treatment is a valuable option for relieving pain in patients with hormone-resistant prostate cancer, despite increases in PSA levels.
Supporting Evidence
- 14 out of 29 patients reported pain relief at 2 months.
- PSA levels increased by a median of 36% at 2 months and 100% at 3 months.
- Alkaline phosphatase levels decreased by about 20% at 2 months.
Takeaway
This study looked at how a treatment called 89Strontium helps people with painful cancer in their bones. It found that many people felt less pain, even though a blood test showed some levels went up.
Methodology
Patients received 150 MBq of 89Strontium intravenously and were evaluated for pain relief and biochemical changes at 2 and 3 months post-treatment.
Potential Biases
Potential bias in subjective pain assessment due to reliance on patient-reported outcomes.
Limitations
The study had a small sample size and the duration of pain relief was shorter than reported in other studies.
Participant Demographics
All participants had hormone-resistant prostate cancer with painful bone metastases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website